Simple Summary Immunotherapy improved the therapeutic landscape for patients with
advanced cancer diseases. However, many patients do not benefit from immunotherapy …

Immunocheckpoint proteins of tumor infiltrating lymphocytes play an important role in tumor
prognosis in the course of tumor clinicopathology. PD‐1 (Programmed cell death protein 1) …

BRD4 is well known for its role in super-enhancer organization and transcription activation
of several prominent oncogenes including c-MYC and BCL2. As such, BRD4 inhibitors are …

Cancer cells resistance to various therapies remains to be a key challenge nowadays. For a
long time, scientists focused on tumor cells themselves for the mechanisms of acquired drug …

Marching into the second decade after the approval of ipilimumab, it is clear that immune
checkpoint inhibitors (ICIs) have dramatically improved the prognosis of melanoma …

The low efficiency of currently-used anti-cancer therapies poses a serious challenge,
especially in the case of malignant melanoma, a cancer characterized by elevated …

Nanoparticle (NP)-mediated drug delivery systems are promising for treating various
diseases. However, clinical translation has been delayed by a variety of limitations, such as …

Simple Summary For decades nearly all cancer patients were treated with cytotoxic
chemotherapy, killing any rapidly dividing cell in the body. More recently, researchers have …

Background We explore sphingolipid-related genes (SRGs) in skin melanoma (SKCM) to
develop a prognostic indicator for patient outcomes. Dysregulated lipid metabolism is linked …

Melanoma is one of the seven most common cancers in the United States, and its incidence
is still increasing. Since 2011, developments in targeted therapies and immunotherapies …